Has Amy Tiersten, MD received payments from drug or device companies?

Yes. Drug and device makers reported $34,781 in general payments to Amy Tiersten, MD across 101 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Amy Tiersten, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Amy Tiersten, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Amy Tiersten, MD

Medical Oncology · New York, NYNPI 1558362566

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $25,050 of the $34,781 with a category attached, or 72.0%. 19 manufacturers reported payments, led by AstraZeneca at 38.4% of the total.

$34,781in general payments, 2019–2025

Across 101 payments — averaging $344.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$13K
Novartis$8K
Genentech USA, Inc.$5K
Athenex Pharmaceutical Division, LLC$4K
Eisai Inc.$2K
AbbVie$1K
plus $2K from 13 others

$17,595,818in research payments, 2019–2025

Across 346 payments — averaging $50,855 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Pfizer$12.5M
Novartis$3.6M
Genentech, Inc.$508K
Gilead$387K
AstraZeneca$249K
Tolmar, Inc.$142K
plus $141K from 3 others

What the payments were for

Consulting fees$25,05072%
Speaking & faculty fees$4,65513%
Travel & lodging$1,6835%
Food & beverage$3,38110%
Education$120%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	14	$13,343
Novartis	32	$8,229
Genentech USA, Inc.	8	$4,504
Athenex Pharmaceutical Division, LLC	5	$4,000
Eisai Inc.	2	$1,675
AbbVie	2	$1,375
Stemline Therapeutics Inc.	8	$383
Daiichi Sankyo Inc.	12	$271
Jazz Pharmaceuticals Inc.	1	$192
Amgen	4	$188
Hologic Sales And Service, LLC	1	$150
Astrazeneca UK Limited	1	$135
GSK	1	$125
Pfizer	2	$60
Merck	3	$50
Gilead	2	$45
Bristol Myers Squibb	1	$24
Puma Biotechnology, Inc.	1	$19
GE HealthCare	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

KISQALI$7,700
Herceptin$4,375
Perjeta$4,375
Oral Paclitaxel$4,000
Encequidar$4,000
Truqap$3,280
Halaven$675
ZIIHERA$192
Orserdu$150
Aptima$150
DATROWAY$135
ZEJULA$125
Prolia$119
XGEVA$119

How this compares

$34,781 in reported general payments places this provider in the 70th percentile of 498 medical oncology providers in New York.

See all medical oncology providers in New York →

Medicare billing

Part B allowed, 2024

$88,787

Medicare patients

346

Services billed

1,012

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Exemestane	128	$17,636
Anastrozole	493	$7,983
Toremifene Citrate	11	$6,153
Estradiol	13	$1,949
Tamoxifen Citrate	72	$1,596
Oxybutynin Chloride	12	$1,189
YuvafemEstradiol	12	$1,100
Letrozole	46	$681
Ondansetron Hcl	25	$308
Prochlorperazine Maleate	17	$296
Dexamethasone	15	$277
Omeprazole	13	$173
Trazodone Hcl	24	$164
Gabapentin	11	$127
Duloxetine Hcl	13	$62

Paid to pharmacies, not to this prescriber.

Other medical oncology in New York

Craig ThompsonNew York$4.8M
Andrew SeidmanNew York$1.3M
Joshua RichterNew York$971K
Edward GelmannNew York$944K
Ghassan Abou-AlfaNew York$825K
Miguel PeralesNew York$769K
Komal JhaveriNew York$642K
Joshua BrodyNew York$492K
Aiwu HeNew York$445K
Raajit RampalNew York$418K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →